文献速递胸部肿瘤

可手术IIIA期非小细胞肺癌新辅助纳武利尤单抗联合化疗的总生存与生物标志物分析(NADIM II期试验)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
PubMed 文献 · J Clin Oncol · 2022-05-16

NADIM是一项开放标签、多中心、单臂II期试验,入组可手术IIIA期非小细胞肺癌患者,接受新辅助紫杉醇+卡铂+纳武利尤单抗3周期,术后纳武利尤单抗辅助治疗1年。36个月总生存率在意向治疗人群为81.9%(95%CI 66.8-90.6),符合方案人群为91.0%(95%CI 74.2-97.0)。治疗前低ctDNA水平及新辅助治疗后ctDNA不可测均与改善的无进展生存和总生存显著相关。

要点

  • 可手术IIIA期NSCLC接受新辅助化疗联合纳武利尤单抗后36个月OS为81.9%(95%CI 66.8-90.6)。
  • 治疗前低ctDNA水平与改善的PFS(HR 0.20)和OS(HR 0.07)显著相关。
  • 新辅助治疗后ctDNA不可测与改善的PFS(HR 0.26)和OS(HR 0.04)显著相关。

核心结论

  • 新辅助化疗联合纳武利尤单抗在可手术NSCLC中的疗效得到3年OS支持。
  • ctDNA水平与OS显著相关,且在预测生存方面优于放射学评估。

研究设计与样本

  • 开放标签、多中心、单臂II期试验(NADIM,NCT03081689)。
  • 入组可手术IIIA期NSCLC患者,接受新辅助紫杉醇(200 mg/m2每日一次)+卡铂(曲线下面积6)+纳武利尤单抗(360 mg)每21天周期第1天给药,共3周期。
  • 术后接受纳武利尤单抗辅助单药治疗1年(240 mg每2周一次共4个月,随后480 mg每4周一次共8个月)。
  • 3年OS和ctDNA分析为次要终点。

主要发现

  • 36个月OS在意向治疗人群为81.9%(95%CI 66.8-90.6),在符合方案人群为91.0%(95%CI 74.2-97.0)。
  • 肿瘤突变负荷和程序性细胞死亡配体-1染色均不能预测生存。
  • 治疗前低ctDNA水平与改善的PFS显著相关(HR 0.20;95%CI 0.06-0.63),与改善的OS显著相关(HR 0.07;95%CI 0.01-0.39)。
  • 根据RECIST v1.1标准的临床缓解不能预测生存结局。
  • 新辅助治疗后ctDNA不可测与改善的PFS显著相关(HR 0.26;95%CI 0.07-0.93),与改善的OS显著相关(HR 0.04;95%CI 0.00-0.55)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported. METHODS: This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA NSCLC, who were deemed to be surgically resectable, were treated with neoadjuvant paclitaxel (200 mg/m2 once a day) and carboplatin (area under curve 6) plus nivolumab (360 mg) once on day 1 of each 21-day cycle, for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 months). The 3-year OS and ctDNA analysis were secondary objectives of the trial. RESULTS: OS at 36 months was 81.9% (95% CI, 66.8 to 90.6) in the intention-to-treat population, rising to 91.0% (95% CI, 74.2 to 97.0) in the per-protocol population. Neither tumor mutation burden nor programmed cell death ligand-1 staining was predictive of survival. Conversely, low pretreatment levels of ctDNA were significantly associated with improved progression-free survival and OS (hazard ratio [HR], 0.20; 95% CI, 0.06 to 0.63, and HR, 0.07; 95% CI, 0.01 to 0.39, respectively). Clinical responses according to RECIST v1.1 criteria did not predict survival outcomes. However, undetectable ctDNA levels after neoadjuvant treatment were significantly associated with progression-free survival and OS (HR, 0.26; 95% CI, 0.07 to 0.93, and HR, 0.04; 95% CI, 0.00 to 0.55, respectively). The C-index to predict OS for ctDNA levels after neoadjuvant treatment (0.82) was superior to that of RECIST criteria (0.72). CONCLUSION: The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year OS. ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Provencio M, Serna-Blasco R, Nadal E, et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J Clin Oncol. 2022. PMID: 35576508. doi:10.1200/JCO.21.02660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。